Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
QUANTIFICATION OF PROSTAGLANDIN-D SYNTHETASE IN CEREBROSPINAL-FLUID -A POTENTIAL MARKER FOR BRAIN-TUMOR
Autore:
SASO L; LEONE MG; SORRENTINO C; GIACOMELLI S; SILVESTRINI B; GRIMA J; LI JCH; SAMY E; MRUK D; CHENG CY;
Indirizzi:
ROCKEFELLER UNIV,POPULAT COUNCIL,1230 YORK AVE NEW YORK NY 10021 ROCKEFELLER UNIV,POPULAT COUNCIL NEW YORK NY 10021 UNIV ROMA LA SAPIENZA,INST PHARMACOL & PHARMACOGNOSY I-00185 ROME ITALY
Titolo Testata:
Biochemistry and molecular biology international
fascicolo: 4, volume: 46, anno: 1998,
pagine: 643 - 656
SICI:
1039-9712(1998)46:4<643:QOPSIC>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENRICHED CULTURE-MEDIUM; TWO-DIMENSIONAL ELECTROPHORESIS; FOLLICLE-STIMULATING HORMONE; GEL-ELECTROPHORESIS; BINDING-PROTEIN; NEUROLOGICAL-DISORDERS; INFLAMMATORY DISORDERS; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; DYE BINDING;
Keywords:
PROSTAGLANDIN D SYNTHETASE; ELISA; BRAIN TUMOR; CEREBROSPINAL FLUID;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
43
Recensione:
Indirizzi per estratti:
Citazione:
L. Saso et al., "QUANTIFICATION OF PROSTAGLANDIN-D SYNTHETASE IN CEREBROSPINAL-FLUID -A POTENTIAL MARKER FOR BRAIN-TUMOR", Biochemistry and molecular biology international, 46(4), 1998, pp. 643-656

Abstract

Prostaglandin D synthetase (PGD-S; prostaglandin-Hz D-isomerase, EC 5,3,99,2), a 30 kDa glycoprotein also known as beta-trace protein that catalyzes the formation of prostaglandin D-2 (PGD(2)) from PGH(2), waspurified to apparent homogeneity from human cerebrospinal fluid (CSF)using a two-step procedure involving HPLC on a Vydac C8 reversed-phase column and high performance electrophoresis chromatography (HPEC) using a 10% T SDS-polyacrylamide gel. The purity of PGD-S isolated from CSF was confirmed by silver stained SDS-polyacrylamide gel and direct protein microsequencing (NH2-APEAQVSVQPNFQ). A highly specific polyclonal antibody was prepared against this protein for immunoassay development. Using an ELISA, it was found that the concentration of PGD-S in CSF did not alter significantly in different pathological conditions of the central nervous system (CNS). These include dementia (n=9), hydrocephalus (n=4), neuropathy (n=11), optic neuritis (n=4), multiple sclerosis (n=11), and demyelinating syndrome (n=11), when compared to normal individuals (n=12); however, the level of PGD-S in the CSF obtained from patients with brain tumor (n=11), was reduced by as much as 2-fold when compared to control samples (n=12) illustrating PGD-S is a potentially useful marker for brain tumor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 07:00:32